Cooperation of protease-activated receptor 1 and integrin ανβ5 in thrombin-mediated lung cancer cell invasion

Zhu,Lingyun; Wang,Xiudong; Wu,Jie; Mao,Dekui; Xu,Zhishan; He,Ziyang; Yu,Aiping

doi:10.3892/or.2012.1851

Cooperation of protease-activated receptor 1 and integrin ανβ5 in thrombin-mediated lung cancer cell invasion

Authors:
- Lingyun Zhu
- Xiudong Wang
- Jie Wu
- Dekui Mao
- Zhishan Xu
- Ziyang He
- Aiping Yu
View Affiliations

Affiliations: Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China
Published online on: June 1, 2012 https://doi.org/10.3892/or.2012.1851
Pages: 553-560

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protease-activated receptor 1 (PAR1) and integrins play an important role in thrombin-mediated tumor cell invasion. However, the role of PAR1 and integrin ανβ5 and the relationship between the two receptors in thrombin-induced lung cancer invasion remains unknown. Moreover, the mechanisms through which immobilized thrombin facilitates tumor invasion are poorly understood. In this study, both native and immobilized thrombin promoted lung cancer cell adhesion, migration and extracellular signal-regulated kinase phosphorylation. Integrin ανβ5 is involved in both native and immobilized thrombin-mediated tumor cell invasion; PAR1 had no effect on immobilized thrombin-mediated cell invasion. PAR1 and integrin ανβ5 colocalized on the surface of native thrombin-treated cells. This study suggests that targeting of integrin ανβ5 or the PAR1-integrin ανβ5 complex may present an important therapeutic opportunity to prevent lung cancer invasion.

View Figures

View References

1	Rickels FR, Levine M and Edwards RL: Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 11:237–248. 1992. View Article : Google Scholar
2	Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM and Melton LJ III: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 160:809–815. 2000. View Article : Google Scholar : PubMed/NCBI
3	Kasthuri R, Taubman M and Mackman N: Role of tissue factor in cancer. J Clin Oncol. 27:4834–4838. 2009. View Article : Google Scholar : PubMed/NCBI
4	Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T and Francis JL: The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost. 33:643–652. 2007. View Article : Google Scholar : PubMed/NCBI
5	Liu Y, Jiang P, Capkova K, Xue D, Ye L, Sinha SC, Mackman N, Janda KD and Liu C: Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res. 71:6492–6502. 2011. View Article : Google Scholar : PubMed/NCBI
6	Hron G, Kollars M, Binder BR, Eichinger S and Kyrle PA: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 296:397–402. 2006. View Article : Google Scholar : PubMed/NCBI
7	Zigler M, Kamiya T, Brantley EC, Villares GJ and Bar-Eli M: PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res. 71:6561–6566. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM and Stump DC: Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol. 93:516–521. 1990.PubMed/NCBI
9	Zacharski LR, Memoli VA, Morain WD, Schlaeppi JM and Rousseau SM: Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost. 73:793–797. 1995.PubMed/NCBI
10	Ornstein DL and Zacharski LR: Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol. 73:157–161. 2001. View Article : Google Scholar : PubMed/NCBI
11	Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and Bar-Shavit R: Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 4:909–914. 1998. View Article : Google Scholar : PubMed/NCBI
12	Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U and Bar-Shavit R: Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer. 113:372–378. 2005. View Article : Google Scholar
13	Henrikson KP, Salazar SL, Fenton JW II and Pentecost BT: Role of thrombin receptor in breast cancer invasiveness. Br J Cancer. 79:401–406. 1999. View Article : Google Scholar : PubMed/NCBI
14	Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A, Bruno K and Lengyel E: Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem. 283:2822–2834. 2008. View Article : Google Scholar : PubMed/NCBI
15	Yang RS, Chiang HS, Tang CH, Yeh CS and Huang TF: Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of alphavbeta3 integrin. Toxicon. 46:387–393. 2005. View Article : Google Scholar : PubMed/NCBI
16	Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutweini P, Altevogti P and Bar-Shavit R: Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha v beta 5 integrin. J Biol Chem. 276:10952–10962. 2001. View Article : Google Scholar : PubMed/NCBI
17	Chiang HS, Yang RS and Huang TF: Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumor cell surface and their inhibition by the snake venom peptide, rhodostomin. Br J Cancer. 73:902–908. 1996. View Article : Google Scholar
18	Chiang HS, Yang RS and Huang TF: The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by Saos-2 human osteosarcoma cells. Br J Cancer. 71:265–270. 1995. View Article : Google Scholar
19	Bode W, Turk D and Karshikov A: The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1:426–471. 1992. View Article : Google Scholar
20	Bar-Shavit R, Sabbah V, Lampugnani MG, Marchisio PC, Fenton JW II, Vlodavsky I and Dejana E: An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion. J Cell Biol. 112:335–344. 1991. View Article : Google Scholar : PubMed/NCBI
21	Bar-Shavit R, Eskohjido Y, Fenton JW II, Esko JD and Vlodavsky I: Thrombin adhesive properties: induction by plasmin and heparan sulfate. J Cell Biol. 123:1279–1287. 1993. View Article : Google Scholar : PubMed/NCBI
22	Tsopanoglou NE, Andriopoulou P and Maragoudakis ME: On the mechanism of thrombin-induced angiogenesis: involvement of alphavbeta3-integrin. Am J Physiol Cell Physiol. 283:C1501–C1510. 2002. View Article : Google Scholar : PubMed/NCBI
23	Tsopanoglou NE, Papaconstantinou ME, Flordellis CS and Maragoudakis ME: On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin. Thromb Haemost. 92:846–857. 2004.PubMed/NCBI
24	Sajid M, Zhao R, Pathak A, Smyth SS and Stouffer GA: Alphavbeta3-integrin antagonists inhibit thrombin-induced proliferation and focal adhesion formation in smooth muscle cells. Am J Physiol Cell Physiol. 285:C1330–C1338. 2003. View Article : Google Scholar : PubMed/NCBI
25	Papaconstantinou ME, Carrell CJ, Pineda AO, Bobofchak KM, Mathews FS, Flordellis CS, Maragoudakis ME, Tsopanoglou NE and Di Cera E: Thrombin functions through its RGD sequence in a non-canonical conformation. J Biol Chem. 280:29393–29396. 2005. View Article : Google Scholar : PubMed/NCBI
26	Bar-Shavit R, Eldor A and Vlodavsky I: Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest. 84:1096–1104. 1989. View Article : Google Scholar : PubMed/NCBI
27	Hernández-Rodríguez NA, Correa E, Sotelo R, Gómez-Ruiz C, Contreras-Paredes A and Green L: Thrombin is present in the lungs of patients with primary extremity osteosarcoma and pulmonary metastases. Int J Biol Markers. 17:189–195. 2002.PubMed/NCBI
28	Fenton JW II: Regulation of thrombin generation and functions. Semin Thromb Hemost. 14:234–240. 1988. View Article : Google Scholar : PubMed/NCBI
29	Weitz JI, Hudoba M, Massel D, Maraganore J and Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:385–391. 1990. View Article : Google Scholar : PubMed/NCBI
30	Begonja AJ, Geiger J, Rukoyatkina N, Rauchfuss S, Gambaryan S and Walter U: Thrombin stimulation of p38 MAP kinase in human platelets is mediated by ADP and thromboxaneA2 and inhibited by cGMP/cGMP-dependent protein kinase. Blood. 109:616–618. 2007. View Article : Google Scholar : PubMed/NCBI
31	Malaver E, Romaniuk MA, D’atri LP, Pozner RG, Negrotto S, Benzadón R and Schattner M: NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost. 7:1333–1343. 2009. View Article : Google Scholar : PubMed/NCBI
32	Shankar H, Garcia A, Prabhakar J, Kim S and Kunapull SP: P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost. 4:638–647. 2006. View Article : Google Scholar
33	Liu J, Schuff-Werner P and Steiner M: Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. Biochem Biophys Res Commun. 343:183–189. 2006. View Article : Google Scholar : PubMed/NCBI
34	Chang LH, Chen CH, Huang DY, Pai HC, Pan SL and Teng CM: Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1α translational pathway in colorectal cancer cells. J Cell Physiol. 226:1060–1068. 2011.PubMed/NCBI
35	Sil H, Sen T and Chatterjee A: Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. Oncol Res. 19:335–348. 2011. View Article : Google Scholar : PubMed/NCBI
36	Hu CT, Wu JR, Cheng CC, Wang S, Wang HT, Lee MC, Wang LJ, Pan SM, Chang TY and Wu WS: Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2. Clin Exp Metastasis. 28:851–863. 2011. View Article : Google Scholar : PubMed/NCBI
37	Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM and Hendrix MJC: Functional role of matrix metalloproteinases in tumor cell plasticity. Am J Obstet Gynecol. 190:899–909. 2004. View Article : Google Scholar : PubMed/NCBI
38	Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM Jr, Cohen MB, Lubaroff DM and Hendrix MJ: Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. 50:189–201. 2002. View Article : Google Scholar
39	Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L and Kuliopulos A: Blocking the protease-activated receptor 1–4 heterodimer in platelet-mediated thrombosis. Circulation. 113:1244–1254. 2006.